MA31109B1 - Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1. - Google Patents

Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1.

Info

Publication number
MA31109B1
MA31109B1 MA32115A MA32115A MA31109B1 MA 31109 B1 MA31109 B1 MA 31109B1 MA 32115 A MA32115 A MA 32115A MA 32115 A MA32115 A MA 32115A MA 31109 B1 MA31109 B1 MA 31109B1
Authority
MA
Morocco
Prior art keywords
group
cyclo
alkyl
alkoxy
optionally substituted
Prior art date
Application number
MA32115A
Other languages
Arabic (ar)
English (en)
Inventor
Takashi Hashihayata
Mikako Kawamura
Morihiro Mitsuya
Yoshiyuki Satoh
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA31109B1 publication Critical patent/MA31109B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un composé de formule générale (i) : (i) dans laquelle ar1 représente un groupe formé à partir d'un cycle aromatique choisi dans un groupe comprenant un indole, un 1h-indazole, un 2h-indazole, un 1h-thiéno[2,3-c]pyrazole, un 1h-pyrazolo[3,4-b]pyridine, un benzo[b]furanne, un benzimidazole, un benzoxazole, un 1,2-benzisoxazole et un imidazo[1,2-a]pyridine ; r1 et r2 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe cyano, un groupe alkényle en c2-c6, un groupe alcoxy en c1-c6, un groupe halo-alcoxy en c1-c6, un groupe cyclo-alkyloxy en c3-c6, un groupe alcanoyle en c2-c7, un groupe halo-alcanoyle en c2-c7, un groupe alcoxycarbonyle en c2-c7, un groupe halo-alcoxycarbonyle en c2-c7, un groupe cyclo-alkyloxycarbonyle en c3-c6, un groupe aralkyloxycarbonyle, un groupe carbamoyl-alcoxy en c1-c6, un groupe carboxy-alkényle en c2-c6 ou un groupe de -q1-n(ra)-q2-rb ; un groupe alkyle en c1-c6, aryle ou hétérocyclique facultativement substitué ; ou un groupe alkyle en c1-c6 ou alkényle en c2-c6 ayant le groupe aryle ou hétérocyclique ; r3 et r4 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe nitro, un groupe cyclo-alkyle en c3-c6, un groupe carbamoyle facultativement substitué avec un groupe alkyle en c1-c6 ou cyclo-alkyle en c3-c6 ou un groupe de -n(re)rf ; un groupe alcanoyle en c2-c7, alcoxy en c1-c6, alcoxycarbonyle en c2-c7, cyclo-alkyloxycarbonyle en c3-c6, alkylsulfonyle en c1-c6, alkylthio en c1-c6, cyclo-alkyloxy en c3-c6, cyclo-alkyle en c3-c6-alcoxy en c1-c6, cyclo-alkylsulfonyle en c3-c6, cyclo-alkylthio en c3-c6 or cyclo-alkyle en c3-c6 alkylthio-c1-c6 facultativement substitué ; ou un groupe alkyle en c1-c6 facultativement substitué ; t et u représentent chacun un atome d'azote ou un groupe méthine ; et v représente un atome d'oxygène ou un atome de soufre. Le composé de l'invention est utilisable en tant qu'agent thérapeutique pour diverses maladies liées à l'acc.
MA32115A 2006-12-28 2009-07-23 Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1. MA31109B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006356575 2006-12-28
JP2007265783 2007-10-11
PCT/JP2007/075240 WO2008081914A1 (fr) 2006-12-28 2007-12-20 Nouveau dérivé d'aminopyrimidine comme inhibiteur de plk1

Publications (1)

Publication Number Publication Date
MA31109B1 true MA31109B1 (fr) 2010-01-04

Family

ID=39588592

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32115A MA31109B1 (fr) 2006-12-28 2009-07-23 Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1.

Country Status (24)

Country Link
US (1) US7977336B2 (fr)
EP (2) EP2116543A4 (fr)
JP (1) JPWO2008081914A1 (fr)
KR (1) KR101481388B1 (fr)
CN (1) CN101573361B (fr)
AR (1) AR064619A1 (fr)
AU (1) AU2007340530B2 (fr)
BR (1) BRPI0718966B8 (fr)
CA (1) CA2668738A1 (fr)
CL (1) CL2007003758A1 (fr)
CO (1) CO6190523A2 (fr)
CR (1) CR10784A (fr)
EC (1) ECSP099324A (fr)
GT (1) GT200900124A (fr)
IL (1) IL198675A0 (fr)
MA (1) MA31109B1 (fr)
MX (1) MX2009004920A (fr)
NO (1) NO20092770L (fr)
NZ (1) NZ577273A (fr)
PE (1) PE20081845A1 (fr)
RU (1) RU2458062C2 (fr)
SV (1) SV2009003258A (fr)
TW (1) TW200835485A (fr)
WO (2) WO2008081910A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114941B1 (fr) 2006-12-22 2015-03-25 Astex Therapeutics Limited Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr
AU2007337895C1 (en) 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010013633A1 (fr) * 2008-07-31 2010-02-04 萬有製薬株式会社 Procédés de prédiction de l'état rb et de la sensibilité à l'inhibiteur de plk1 d'une cellule
JP4489132B2 (ja) * 2008-08-22 2010-06-23 株式会社東芝 磁気記録媒体の製造方法
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8445674B2 (en) 2009-10-21 2013-05-21 Hoffmann-La Roche Inc Heterocyclyl compounds
EP2493889B1 (fr) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. Dérivés d'imidazo[1,2-b]pyridazine et leur utilisation en tant qu'inhibiteurs pde10
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2463289A1 (fr) 2010-11-26 2012-06-13 Almirall, S.A. Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
CU24269B1 (es) 2011-09-27 2017-08-08 Novartis Ag 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
EP2863909B1 (fr) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinaisons comprenant des dérivés de 4-méthyl-[1,2,4]triazolo[4,3-a]quinoxaline comme inhibiteurs de la pde 2 et des inhibiteurs de la pde 10 pour utilisation dans le traitement de troubles neurologiques ou métaboliques
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
ES2668861T3 (es) 2012-07-31 2018-05-22 Crown Bioscience, Inc. (Taicang) Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR
WO2014046617A1 (fr) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions et méthodes de traitement du cancer
WO2016041845A1 (fr) 2014-09-17 2016-03-24 Boehringer Ingelheim International Gmbh Dérivés de tétrahydroisoquinoline et compositions pharmaceutiques utiles pour le traitement de l'obésité et du diabète
EP3997088A4 (fr) * 2019-07-10 2022-12-28 Aucentra Therapeutics Pty Ltd Dérivés de 4-(imidazo [l, 2-a] pyridine-3-yl)-n-(pyridinyl) pyrimidine-2-amine en tant qu'agents thérapeutiques
CN112592318B (zh) * 2020-12-12 2022-05-03 贵州医科大学 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FI95708C (fi) 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
JPH045029A (ja) 1990-04-23 1992-01-09 Bridgestone Corp 空気入りタイヤ
DE69131775T2 (de) 1990-09-28 2000-04-20 Smithkline Beecham Corp. Verfahren zur Herstellung wasserlöslicher Camptothecinanaloge, sowie die Verbindungen 10-Hydroxy-11-C(1-6)-alkoxycamptothecin
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2222231A1 (fr) 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
PT1140939E (pt) * 1999-11-10 2005-05-31 Ortho Mcneil Pharm Inc 2-aril-3-(heteroaril)- imidazo [1,2-alfa] pirimidinas substituidas, e formulacoes farmaceuticas e metodos relacionados
AU2002237704A1 (en) 2000-12-04 2002-06-18 Sepracor, Inc. Methods for the stereoselective synthesis of substituted piperidines
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
WO2003011285A1 (fr) 2001-08-01 2003-02-13 Merck & Co., Inc. Derives de la benzimidazo[4,5-f]isoquinolinone
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004043936A1 (fr) 2002-11-14 2004-05-27 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de plk (kinases du type polo)
CA2559733C (fr) 2004-03-26 2014-05-13 Methylgene Inc. Inhibiteurs d'histone desacetylase
EP1790650B1 (fr) 2004-08-31 2014-03-26 Msd Kk Nouveaux dérivés d'imidazoles substitués

Also Published As

Publication number Publication date
SV2009003258A (es) 2010-08-23
EP2114942A4 (fr) 2010-09-08
US7977336B2 (en) 2011-07-12
RU2009128966A (ru) 2011-02-10
EP2116543A1 (fr) 2009-11-11
NO20092770L (no) 2009-09-25
KR101481388B1 (ko) 2015-01-12
CA2668738A1 (fr) 2008-07-10
AR064619A1 (es) 2009-04-15
BRPI0718966B1 (pt) 2020-11-17
US20080305081A1 (en) 2008-12-11
BRPI0718966A2 (pt) 2014-01-07
EP2114942B1 (fr) 2012-10-31
EP2114942A1 (fr) 2009-11-11
JPWO2008081914A1 (ja) 2010-04-30
MX2009004920A (es) 2009-05-21
WO2008081910A1 (fr) 2008-07-10
RU2458062C2 (ru) 2012-08-10
EP2116543A4 (fr) 2010-09-08
GT200900124A (es) 2010-11-03
IL198675A0 (en) 2010-02-17
CL2007003758A1 (es) 2008-07-04
TW200835485A (en) 2008-09-01
ECSP099324A (es) 2009-06-30
WO2008081914A1 (fr) 2008-07-10
PE20081845A1 (es) 2008-12-27
CR10784A (es) 2009-09-16
NZ577273A (en) 2011-03-31
AU2007340530A1 (en) 2008-07-10
KR20090092822A (ko) 2009-09-01
CN101573361B (zh) 2012-05-30
CO6190523A2 (es) 2010-08-19
BRPI0718966B8 (pt) 2021-05-25
CN101573361A (zh) 2009-11-04
AU2007340530B2 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
MA31109B1 (fr) Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1.
MA31108B1 (fr) Derives substitues de spirochromanone en tant qu'inhibiteurs d'acc
WO2008088692A3 (fr) Dérivés spirochromanone
Cheong et al. A patent review of IDO1 inhibitors for cancer
Ravi et al. N-chlorosuccinimide-promoted regioselective sulfenylation of imidazoheterocycles at room temperature
Campiani et al. Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT3 receptor agonists: synthesis, further structure− activity relationships, and biological studies
Chandna et al. Synthesis of novel celecoxib analogues by bioisosteric replacement of sulfonamide as potent anti-inflammatory agents and cyclooxygenase inhibitors
Manetti et al. Identification of a novel pyrazolo [3, 4-d] pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice
CA3015271C (fr) Derives de dioxyde d'iminothiadiazinane utilises comme inhibiteurs de la plasmepsine v
ZA200500022B (en) 1-(Aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligans
Shiro et al. 7-Phenyl-imidazoquinolin-4 (5H)-one derivatives as selective and orally available mPGES-1 inhibitors
TW200413379A (en) Fused azole-pyrimidine derivatives
PT97960A (pt) Processo de oxidacao de arilsulfetos a arilsulfoxidos
AU2018326721B2 (en) Compounds and compositions for IRE1 inhibition
Wurz et al. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors
Tiwari et al. Copper-catalyzed synthesis of benzoxazoles via tandem cyclization of 2-halophenols with amidines
Chezal et al. Heterocyclization of functionalized vinylic derivatives of imidazo [1, 2-a] pyridines
Zeng et al. Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization
Liu et al. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo [1, 5-a] pyrazine core featuring 3-position bicyclic ring substitutes
Jiang et al. Regio-and diastereoselective synthesis of 3, 4-dihydro-2H-benzo [4, 5] imidazo [2, 1-b][1, 3] thiazine derivatives via DBU-catalyzed [3+ 3] annulation of MBH carbonates with 2-mercaptobenzimidazoles
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
ATE337827T1 (de) N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel
WO2015106158A1 (fr) Composés organiques
Lauria et al. Pyrazolo [3, 4-d][1, 2, 3] triazolo [1, 5-a] pyrimidine: a new ring system through Dimroth rearrangement
Sun et al. Synthesis of Organofluoro Compounds Using Methyl Perfluoroalk‐2‐ynoates as Building Blocks